RaDaR ST (Solid Tumor) – Minimal Residual Disease (MRD) Testing
List Price: $3,750 (per plasma timepoint)
RaDaR ST is a tumor-informed circulating tumor DNA (ctDNA) molecular residual disease assay. This test includes multiplex polymerase chain reaction (PCR) and next-generation sequencing (NGS) for the detection of ctDNA in the cell-free DNA extracted from a plasma specimen, utilizing a previously developed patient-specific assay.
The list price reflects the standard charge for a single plasma-based MRD assessment (follow-up timepoint). Initial components of the RaDaR testing workflow, including assay development from tumor sequencing and initial MRD assessment, are billed separately.
RaDaR ST Tumor Profiling + Minimal Residual Disease (MRD) Testing Single Timepoint (Whole Exome Sequencing + 1 MRD Test)
List Price $8,400
This test includes whole exome sequencing (WES) of a tumor specimen for development of a patient specific assay, followed by multiplex polymerase chain reaction (PCR) and next-generation sequencing (NGS) for the detection of ctDNA in cell-free DNA extracted from a plasma specimen. This service is ordered in advance of a single (follow-up) plasma-based MRD monitoring assay.